Ximelagatran: A new oral anticoagulant

Best Practice and Research: Clinical Haematology

Volumn 17, Issue 1, 2004, Pages 139-152

  Francis, Charles W ^a  

^a UNIVERSITY OF ROCHESTER SCHOOL OF MEDICINE AND DENTISTRY   (United States)

Author keywords

Atrial fibrillation; Coumarins; Deep vein thrombosis; MElagatran; Myocardial infarction; Pulmonary embolism; Stroke; Vitamin K antgonists; Warfarin; Ximelagatran

Indexed keywords

ANTICOAGULANT AGENT; ANTITHROMBIN III; ANTIVITAMIN K; ARGATROBAN; BLOOD CLOTTING FACTOR 10A; DALTEPARIN; DESULFATOHIRUDIN; ENOXAPARIN; FONDAPARINUX; HEPARIN; HIRUDIN; HIRULOG; LOW MOLECULAR WEIGHT HEPARIN; MELAGATRAN; PLACEBO; PRODRUG; THROMBIN; THROMBIN INHIBITOR; WARFARIN; XIMELAGATRAN;

ACUTE HEART INFARCTION; ALANINE AMINOTRANSFERASE BLOOD LEVEL; AMINOTRANSFERASE BLOOD LEVEL; AREA UNDER THE CURVE; ARTICLE; BILIRUBIN BLOOD LEVEL; BLEEDING DISORDER; BLOOD CLOTTING TEST; CLINICAL TRIAL; DEEP VEIN THROMBOSIS; DRUG ABSORPTION; DRUG EFFICACY; DRUG HALF LIFE; DRUG MECHANISM; DRUG METABOLISM; DRUG SAFETY; EMBOLISM; FOOD DRUG INTERACTION; HEART ATRIUM FIBRILLATION; HUMAN; JAUNDICE; LIVER DYSFUNCTION; LIVER FUNCTION TEST; LIVER INJURY; LIVER TOXICITY; LUNG EMBOLISM; MONITORING; ORTHOPEDIC SURGERY; PREDICTION; PRIORITY JOURNAL; RECURRENT DISEASE; RELIABILITY; STROKE; SYMPTOMATOLOGY; THROMBOCYTOPENIA; THROMBOSIS PREVENTION; URINARY EXCRETION; VENOUS THROMBOEMBOLISM;

EID: 2942684886     PISSN: 15216926     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.beha.2004.03.005     Document Type: Review

References (37)

1. Gonze MD, Manord JD, Leone-Bay A, et al. Orally administered heparin for preventing deep venous thrombosis. American Journal of Surgery 1998; 176: 176-178.
2. Baughman RA, Kapoor SC, Agarwal RK, et al. Oral delivery of anticoagulant doses of heparin. A randomized, double-blind, controlled study in humans. Circulation 1998; 98: 1610-1615.
3. Pineo GF, Hull RD & Marder VJ. Orally active heparin and low-molecular-weight heparin. Current Opinions of Pulmonary Medicine 2001; 7: 344-348.
4. Moll S & Roberts HR. Overview of anticoagulant drugs for the future. Seminars in Hematology 2002; 39: 145-157.
5. Sato K, Kawasaki T, Taniuchi Y, et al. YM-60828, a novel factor Xa inhibitor: separation of its antithrombotic effects from its prolongation of bleeding time. European Journal of Pharmacology 1997; 339: 141-146.
6. Jenny NS & Mann KG. Thrombin. In Colman RW, Hirsh J & Marder VJ (eds) Hemostasis and Thrombosis: Basic Principles and Practice, 4th edn. ; 2001, pp 171-189.
7. Kaplan KL & Francis CW. Direct thrombin inhibitors. Seminars in Hematology 2002; 39: 187-196.
8. Bauer KA. Selective inhibition of coagulation factors: advances in antithrombotic therapy. Seminars in Thromobsis and Hemostasis 2002; 28(supplement 2): 15-24.
9. Gustafsson D, Nystrom J, N S, et al. The direct thrombin inhibitor melagatran and its oral prodrug H 376/95: intestinal absorption properties, biochemical and pharmacodynamic effects. Thrombosis Research 2001; 101: 171-181.
10. Eriksson UG, Bredberg U, Hoffmann KJ, et al. Absorption, distribution, metabolism, and excretion of ximelagatran, an oral direct thrombin inhibitor, in rats, dogs, and humans. Drug Metabolism and Disposition 2003; 31: 294-305.
11. Gustafsson D, Antonsson T, Bylund R, et al. Effects of melagatran, a new low-molecular-weight thrombin inhibitor, on thrombin and fibrinolytic enzymes. Thrombosis and Haemostasis 1998; 79: 110-118.
12. Elg M, Gustafsson D & Deinum J. The importance of enzyme inhibition kinetics for the effect of thrombin inhibitors in a rat model of arterial thrombosis. Thrombosis and Haemostasis 1997; 78: 1286-1292.
13. Deinum J, Gustavsson L, Gyzander E, et al. A thermodynamic characterization of the binding of thrombin inhibitors to human thrombin, combining biosensor technology, stopped-flow spectrophotometry, and microcalorimetry. Analytical Biochemistry 2002; 300: 152-162.
14. Johansson LC, Frison L, Logren U, et al. Influence of age on the pharmacokinetics and pharmacodynamics of ximelagatran, an oral direct thrombin inhibitor. Clinical Pharmacokinetics 2003; 42: 381-392.
15. Wahlander K, Lapidus L, Olsson CG, et al. Pharmacokinetics, pharmacodynamics and clinical effects of the oral direct thrombin inhibitor ximelagatran in acute treatment of patients with pulmonary embolism and deep vein thrombosis. Thrombosis Research 2002; 107: 93-99.
16. Klement P, Carlsson S, RakJ, et al. The benefit-to-risk profile of melagatran is superior to that of hirudin in a rabbit arterial thrombosis prevention and bleeding model. Journal of Thrombosis Haemostasis 2003; 1: 587-594.
17. Mattsson C, Menschik-Lundin A, Nylander S, et al. Effect of different types of thrombin inhibitors on thrombin/thrombomodulin modulated activation of protein C in vitro. Thrombosis Research 2001; 104: 475-486.
18. Linder R, Frebelius S, Jansson K, et al. Inhibition of endothelial cell-mediated generation of activated protein C by direct and antithrombin-dependent thrombin inhibitors. Blood Coagulation and Fibrinolysis 2003; 14: 139-146.
19. Nylander S & Mattsson C. Thrombin-induced platelet activation and its inhibition by anticoagulants with different modes of action. Blood Coagulation and Fibrinolysis 2003; 14: 159-167.
20. Sarich TC, Wolzt M, Eriksson UG, et al. Effects of ximelagatran, an oral direct thrombin inhibitor, r-hirudin and enoxaparin on thrombin generation and platelet activation in healthy male subjects. Journal of American College of Cardiology 2003; 41: 557-564.
21. Hauptmann J. Pharmacokinetics of an emerging new class of anticoagulant/antithrombotic drugs. A review of small-molecule thrombin inhibitors. European Journal of Clinical Pharmacology 2002; 57: 751-758.
22. Eriksson H, Eriksson UG, Frison L, et al. Pharmacokinetics and pharmacodynamics of melagatran, a novel synthetic LMW thrombin inhibitor, in patients with acute DVT. Thrombosis and Haemostasis 1999; 81: 358-363.
23. Mattsson C, Menschiek-Lundin A, Wahlander K, et al. Effect of melagatran on prothrombin time assays depends on the sensitivity of the thromboplastin and the final dilution of the plasma sample. Thrombosis and Haemostasis 2001; 86: 611-615.
24. Hafner G, Roser M & Nauck M. Methods for the monitoring of direct thrombin inhibitors. Seminars in Thrombosis and Hemostasis 2002; 28: 425-430.
25. Eriksson BI, Bergqvist D, Kalebo P, et al. Ximelagatran and melagatran compared with dalteparin for prevention of venous thromboembolism after total hip or knee replacement: the METHRO II randomised trial. Lancet 2002; 360: 1441-1447.
26. Eriksson BI, Agnelli G, Cohen AT, et al. Direct thrombin inhibitor melagatran followed by oral ximelagatran in comparison with enoxaparin for prevention of venous thromboembolism after total hip or knee replacement. Thrombosis and Haemostasis 2003; 89: 288-296.
27. Eriksson BI. The oral direct thrombin inhibitor ximelagatran, and its subcutaneous (sc) form melagatran, compared with enoxaparin for prophylaxis of venous thromboembolism (VTE) in total hip or total knee replacement (THR or TKR): the EXPRESS study. Blood 2002; 100: 82a.
28. Heit JA, Colwell CW, Francis CW, et al. Comparison of the oral direct thrombin inhibitor ximelagatran with enoxaparin as prophylaxis against venous thromboembolism after total knee replacement: a phase 2 dose-finding study. Archieves of Internal Medicine 2001; 161: 2215-2221.
29. Francis CW, Davidson BL, Berkowitz SD, et al. Ximelagatran versus warfarin for the prevention of venous thromboembolism after total knee arthroplasty. A randomized, double-blind trial. Annals of Internal Medicine 2002; 137: 648-655.
30. Francis CW, Berkowitz SD, Comp PC, et al. Comparison of ximelagatran with warfarin for the prevention of venous thromboembolism after total knee replacement. New England Journal of Medicine 2003; 349: 1703-1712.
31. Colwell CW, Berkowitz SD, Davidson BL, et al. Comparison of ximelagatran, an oral direct thrombin inhibitor, with enoxaparin for the prevention of venous thromboembolism following total hip replacement. A randomized, double-blind study. Journal of Thrombosis and Haemostasis 2003; 1: 2119-2130.
32. Eriksson H, Wahlander K, Gustafsson D, et al. A randomized, controlled, dose-guiding study of the oral direct thrombin inhibitor ximelagatran compared with standard therapy for the treatment of acute deep vein thrombosis: THRIVE I. Journal of Thrombosis and Haemostasis 2003; 1: 41-47.
33. Schulman S, Wahlander K, Lundstrom T, et al. Secondary prevention of venous thromboembolism with the oral direct thrombin inhibitor ximelagatran. New England Journal of Medicine 2003; 349: 1713-1721.
34. Eriksson H, Wahlander K & Lundstrom T Extended secondary prevention with the oral direct thrombin inhibitor ximelagatran for 18 months after 6 months of anticoagulation in patients with venous thromboembolism: a randomized, placebo-controlled trial. Blood 2002; 100: 81a.
35. Huisman M. Efficancy and safety of the oral direct thrombin inhibitor ximelagatran compared with current standard therapy for acute symptomatic deep vein thrombosis with or without pulmonary embolism, a double-blind, multinational trial. Abstracts of the XIX Congress of the ISTH, 2003..
36. Halperin J. The stroke prophylaxic using an oral thrombin inhibitor in atrial fibrillation trial (SPORTIF III). American Heart Journal 2003; : 146.
37. Wallentin L, Wilcox RG, Weaver WD, et al. Oral ximelagatran for secondary prophylaxis after myocardial infarction: the ESTEEM randomised controlled trial. Lancet 2003; 362: 789-797.